CD34 Selection of the Peripheral Blood Stem Cell Graft for Autologous Transplant

Not Recruiting

Trial ID: NCT00186680

Age - 19 Years-70 Years Condition - Breast Cancer Gender - All Accepting Healthy Volunteers - No

Purpose

Evaluate the feasibility and safety of autologous transplantation of CD34+Thy-1+ hematopoietic stem cells afer high dose marrow ablative chemotherapy in patients with breast cancer.

Official Title

Selection of CD34+THY-1 Positive Cells From Peripheral Blood Cells Procured for Autologous Hematopoietic Support Following High Dose Treatment With BCNU, Cyclophosphamide & Cisplatin for Stage IV Breast Cancer & Limited Prior Treatment

Eligibility


Inclusion Criteria:- stage IV breast cancer

   - primary breast cancer does not express CD34+

   - adequate organ function

   - no evidence of active infection Exclusion Criteria:- chemotherapy within 4 weeks

   - CNS disease

View More
View Less

Intervention(s):

procedure: high dose chemo then auto hematopoietic cell transplant

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
BMT Referrals
6507230822

New Trial Alerts

©2024 Stanford Medicine